Friday, April 13, 2007 Capitol Hill
Watch
Senate Committee Approves Legislation That Would
Allow Federal Government To Negotiate Medicare Prescription Drug
Prices
The Senate Finance
Committee on Thursday voted 13-8 to approve legislation sponsored by
committee Chair Max Baucus (D-Mont.) that would allow the government to
negotiate prices with pharmaceutical companies under the Medicare
prescription drug benefit, AP/Long Island Newsday reports (Freking,
AP/Long Island Newsday, 4/12). The House in January passed a
bill (HR 4) that would require the HHS secretary to negotiate prices directly with
pharmaceutical companies under the drug benefit and report to Congress in
six months. The Senate legislation would lift the ban barring the HHS
secretary from negotiating drug prices. Under the Senate bill,
congressional agencies such as the Congressional Budget Office would be given access to
information about rebates and discounts that drug plans are negotiating
with drug manufacturers. The agencies would use the data to inform
Congress on how the drug plans are performing with regard to decreasing
costs. The bill also includes a provision that would require the HHS
secretary to compile a list of research and studies that compare the
effectiveness of drugs and medical devices, which could be used by
insurers to decide which drugs to cover (Kaiser Daily Health Policy Report, 4/12). Two
Republican committee members -- Sens. Olympia Snowe (Maine) and Gordon
Smith (Ore.) -- joined the committee's 11 Democrats in approving the
legislation (AP/Long Island Newsday, 4/12). The full Senate
is expected to consider the bill during the second half of next week, and
Democratic leaders are making an effort to secure enough votes to overcome
an expected filibuster attempt (Kivlan, CongressDaily, 4/12).
According to the Wall Street Journal, some Democratic
senators are hoping that Sens. Norm Coleman (R-Minn.) and Ben Nelson
(D-Neb.) can be persuaded to support the bill. However, Nelson said, "It
may be too early to make that type of adjustment" to Medicare (Wall
Street Journal, 4/13).
Comments
Sen. Kent Conrad (D-N.D.) said that the bill would
give the federal government the power to achieve lower prescription drug
prices. "When you're negotiating on behalf of 43 million people, that's
leverage," Conrad said. However, committee ranking member Chuck Grassley
(R-Iowa) said that the Medicare drug benefit already is lowering drug
prices. "This bill does nothing more than keep alive a political pandering
approach Democratic leaders have committed against Medicare beneficiaries
and the public on the issue," Grassley said (AP/Long Island
Newsday, 4/12). Earlier in the day, HHS Secretary Mike
Leavitt said, "There's no evidence if government interferes with the
market it would lower costs," adding, "The system is working" (Carey, CQ HealthBeat, 4/12).
American Public
Media's "Marketplace Morning Report" on Friday reported on the
committee vote. The segment includes comments from Richard Frank, a
professor of health economics at Harvard University (Loeb, " Marketplace Morning Report,"
American Public Media, 4/13). Audio and a transcript of the segment are
available online.